touchONCOLOGY editorial board member Professor Robin Foà (Sapienza University of Rome, Italy) discusses his recent phase II study exploring the benefits, efficacy and safety of tyrosine kinase inhibitors dasatinib–blinatumomab for the treatment of Ph-positive acute lymphoblastic leukemia in adults.
- What is the rationale for the use of dasatinib plus glucocorticoids, followed by blinatumomab, rather than chemotherapy, in the treatment of adults with newly diagnosed? Ph+ acute lymphoblastic leukemia? 00:12-02:30
- Could you give us a brief overview of the Phase II study investigating this regimen? 02:30-04:14
- What were the efficacy, safety and tolerability findings of the study? 04:14-07:02
- Which patients are most likely to benefit from this regimen? 07:02-08:39
- What questions remain unanswered and what future studies are planned? 08:39-11:43
- Please summarise the findings from the ancillary studies? 11:43-13:42
- Please discuss the importance of laboratory testing, home treatment and the benefits of this approach during the COVID-19 pandemic 13:42-16:13
Speaker Disclosure: Robin Foà has no financial or non-financial conflicts of interest to declare in relation to this video.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Sophie Nickelson.
Share this Video
Related Videos In Leukaemia
PART ONE: Nicholas Short, EHA 2022: Ponatinib and blinatumomab in patients with PH+ALL: Results of a phase II study
In Part One of this video interview, Prof Nicholas Short (The University of Texas MD Anderson Cancer Center, Houston, TX, USA) discusses his phase II trial looking at ponatinib and blinatumomab for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia. A total of 55 patients were treated and the combination therapy showed complete molecular response. These […]
PART TWO: Nicholas Short, EHA 2022: Ponatinib and blinatumomab in patients with PH+ALL: Results of a phase II study
In Part Two of this video interview, Prof Nicholas Short (The University of Texas MD Anderson Cancer Center, Houston, TX, USA) summaries the rationale, design and eligibility criteria of his phase II trial looking at ponatinib and blinatumomab for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia, and summarizes the key take-home conclusions. A total of […]
Jorge Cortes, EHA 2022: Magrolimab plus azacitidine in the patients with AML and HR MDS
Professor Jorge Cortes (Georgia Cancer Center, Augusta, GA, USA) summarizes two more important abstracts from the 27th Congress of the European Hematology Association (EHA) looking at magrolimab, an antibody blocking CD47, “don’t eat me” signal on cancer cells. The first is a phase III trial (NCT05079230) assessing magrolimab in combination with venetoclax and azacitidine in […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!